用于原发性前列腺癌正电子发射断层扫描(PET)成像的胃泌素释放肽受体(GRPr)靶向示踪剂的检出率:系统综述和荟萃分析

IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Gokce Belge Bilgin, Cem Bilgin, Atakan Orscelik, Brian J. Burkett, Matthew P. Thorpe, Derek R. Johnson, Geoffrey B. Johnson, David F. Kallmes, Oliver Sartor, Ayse Tuba Kendi
{"title":"用于原发性前列腺癌正电子发射断层扫描(PET)成像的胃泌素释放肽受体(GRPr)靶向示踪剂的检出率:系统综述和荟萃分析","authors":"Gokce Belge Bilgin,&nbsp;Cem Bilgin,&nbsp;Atakan Orscelik,&nbsp;Brian J. Burkett,&nbsp;Matthew P. Thorpe,&nbsp;Derek R. Johnson,&nbsp;Geoffrey B. Johnson,&nbsp;David F. Kallmes,&nbsp;Oliver Sartor,&nbsp;Ayse Tuba Kendi","doi":"10.1007/s12149-024-01978-6","DOIUrl":null,"url":null,"abstract":"<div><p>The gastrin-releasing peptide receptor (GRPr) has gained recognition as a promising target for both diagnostic and therapeutic applications in a variety of human cancers. This study aims to explore the primary tumor detection capabilities of [<sup>68</sup>Ga] Ga-GRPr PET imaging, specifically in newly diagnosed intra-prostatic prostate cancer lesions (PCa). Following PRISMA-DTA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies) guidelines, a systematic literature search was conducted using the Medline, Embase, Scopus, and Web of Science databases. Data regarding patient characteristics and imaging procedure details—including the type of radiotracer used, administered activity, image acquisition time, scanner modality, criteria, and detection rate of index test—were extracted from the included studies. The pooled patient-and lesion-based detection rates, along with their corresponding 95% confidence intervals (CI), were calculated using a random effects model. The final analysis included 9 studies involving 291 patients and 350 intra-prostatic lesions with [<sup>68</sup>Ga] Ga-GRPr PET imaging in primary PCa. In per-patient-based analysis of [<sup>68</sup>Ga] Ga-GRPr PET imaging, the pooled detection rates of overall and patients with Gleason score ≥ 7 were 87.09% (95% CI 74.98–93.82) and 89.01% (95% CI 68.17–96.84), respectively. In per-lesion-based analysis, the pooled detection rate [<sup>68</sup>Ga] Ga-GRPr PET imaging was 78.54% (95% CI 69.8–85.29). The pooled detection rate mpMRI (multiparametric magnetic resonance imaging) in patient-based analysis was 91.85% (95% CI 80.12–96.92). The difference between the detection rates of the mpMRI and [<sup>68</sup>Ga] Ga-GRPr PET imaging was not statistically significant (OR 0.90, 95% CI 0.23–3.51). Our findings suggest that [<sup>68</sup>Ga] Ga-GRPr PET imaging has the potential as a diagnostic target for primary PCa. Future research is needed to determine the effectiveness of [<sup>68</sup>Ga] Ga-GRPr PET in delivering additional imaging data and guiding therapeutic decisions.</p></div>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":"38 11","pages":"865 - 876"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis\",\"authors\":\"Gokce Belge Bilgin,&nbsp;Cem Bilgin,&nbsp;Atakan Orscelik,&nbsp;Brian J. Burkett,&nbsp;Matthew P. Thorpe,&nbsp;Derek R. Johnson,&nbsp;Geoffrey B. Johnson,&nbsp;David F. Kallmes,&nbsp;Oliver Sartor,&nbsp;Ayse Tuba Kendi\",\"doi\":\"10.1007/s12149-024-01978-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The gastrin-releasing peptide receptor (GRPr) has gained recognition as a promising target for both diagnostic and therapeutic applications in a variety of human cancers. This study aims to explore the primary tumor detection capabilities of [<sup>68</sup>Ga] Ga-GRPr PET imaging, specifically in newly diagnosed intra-prostatic prostate cancer lesions (PCa). Following PRISMA-DTA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies) guidelines, a systematic literature search was conducted using the Medline, Embase, Scopus, and Web of Science databases. Data regarding patient characteristics and imaging procedure details—including the type of radiotracer used, administered activity, image acquisition time, scanner modality, criteria, and detection rate of index test—were extracted from the included studies. The pooled patient-and lesion-based detection rates, along with their corresponding 95% confidence intervals (CI), were calculated using a random effects model. The final analysis included 9 studies involving 291 patients and 350 intra-prostatic lesions with [<sup>68</sup>Ga] Ga-GRPr PET imaging in primary PCa. In per-patient-based analysis of [<sup>68</sup>Ga] Ga-GRPr PET imaging, the pooled detection rates of overall and patients with Gleason score ≥ 7 were 87.09% (95% CI 74.98–93.82) and 89.01% (95% CI 68.17–96.84), respectively. In per-lesion-based analysis, the pooled detection rate [<sup>68</sup>Ga] Ga-GRPr PET imaging was 78.54% (95% CI 69.8–85.29). The pooled detection rate mpMRI (multiparametric magnetic resonance imaging) in patient-based analysis was 91.85% (95% CI 80.12–96.92). The difference between the detection rates of the mpMRI and [<sup>68</sup>Ga] Ga-GRPr PET imaging was not statistically significant (OR 0.90, 95% CI 0.23–3.51). Our findings suggest that [<sup>68</sup>Ga] Ga-GRPr PET imaging has the potential as a diagnostic target for primary PCa. Future research is needed to determine the effectiveness of [<sup>68</sup>Ga] Ga-GRPr PET in delivering additional imaging data and guiding therapeutic decisions.</p></div>\",\"PeriodicalId\":8007,\"journal\":{\"name\":\"Annals of Nuclear Medicine\",\"volume\":\"38 11\",\"pages\":\"865 - 876\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12149-024-01978-6\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12149-024-01978-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

胃泌素释放肽受体(GRPr)已被公认为是多种人类癌症的诊断和治疗应用的前景良好的靶点。本研究旨在探索[68Ga] Ga-GRPr PET 成像的原发性肿瘤检测能力,特别是在新诊断的前列腺内病变(PCa)中的检测能力。根据 PRISMA-DTA(诊断测试准确性研究的系统综述和元分析的首选报告项目)指南,我们使用 Medline、Embase、Scopus 和 Web of Science 数据库进行了系统的文献检索。从纳入的研究中提取了有关患者特征和成像过程细节的数据,包括所用放射性示踪剂的类型、给药活性、图像采集时间、扫描仪模式、标准和指标检测的检出率。采用随机效应模型计算出患者和病灶的综合检出率及其相应的 95% 置信区间 (CI)。最终的分析包括9项研究,涉及291名患者和350个睾丸内病灶,对原发性PCa进行了[68Ga] Ga-GRPr PET成像。在基于每位患者的[68Ga] Ga-GRPr PET成像分析中,总体和Gleason评分≥7分患者的集合检出率分别为87.09%(95% CI 74.98-93.82)和89.01%(95% CI 68.17-96.84)。在基于每个病灶的分析中,[68Ga] Ga-GRPr PET 成像的总检出率为 78.54%(95% CI 69.8-85.29)。在基于患者的分析中,mpMRI(多参数磁共振成像)的总检出率为 91.85%(95% CI 80.12-96.92)。mpMRI 和[68Ga] Ga-GRPr PET 成像的检出率差异无统计学意义(OR 0.90,95% CI 0.23-3.51)。我们的研究结果表明,[68Ga] Ga-GRPr PET 成像有可能成为原发性 PCa 的诊断靶点。未来的研究需要确定[68Ga] Ga-GRPr PET在提供更多成像数据和指导治疗决策方面的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis

Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis

Detection rate of gastrin-releasing peptide receptor (GRPr) targeted tracers for positron emission tomography (PET) imaging in primary prostate cancer: a systematic review and meta-analysis

The gastrin-releasing peptide receptor (GRPr) has gained recognition as a promising target for both diagnostic and therapeutic applications in a variety of human cancers. This study aims to explore the primary tumor detection capabilities of [68Ga] Ga-GRPr PET imaging, specifically in newly diagnosed intra-prostatic prostate cancer lesions (PCa). Following PRISMA-DTA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies) guidelines, a systematic literature search was conducted using the Medline, Embase, Scopus, and Web of Science databases. Data regarding patient characteristics and imaging procedure details—including the type of radiotracer used, administered activity, image acquisition time, scanner modality, criteria, and detection rate of index test—were extracted from the included studies. The pooled patient-and lesion-based detection rates, along with their corresponding 95% confidence intervals (CI), were calculated using a random effects model. The final analysis included 9 studies involving 291 patients and 350 intra-prostatic lesions with [68Ga] Ga-GRPr PET imaging in primary PCa. In per-patient-based analysis of [68Ga] Ga-GRPr PET imaging, the pooled detection rates of overall and patients with Gleason score ≥ 7 were 87.09% (95% CI 74.98–93.82) and 89.01% (95% CI 68.17–96.84), respectively. In per-lesion-based analysis, the pooled detection rate [68Ga] Ga-GRPr PET imaging was 78.54% (95% CI 69.8–85.29). The pooled detection rate mpMRI (multiparametric magnetic resonance imaging) in patient-based analysis was 91.85% (95% CI 80.12–96.92). The difference between the detection rates of the mpMRI and [68Ga] Ga-GRPr PET imaging was not statistically significant (OR 0.90, 95% CI 0.23–3.51). Our findings suggest that [68Ga] Ga-GRPr PET imaging has the potential as a diagnostic target for primary PCa. Future research is needed to determine the effectiveness of [68Ga] Ga-GRPr PET in delivering additional imaging data and guiding therapeutic decisions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Nuclear Medicine
Annals of Nuclear Medicine 医学-核医学
CiteScore
4.90
自引率
7.70%
发文量
111
审稿时长
4-8 weeks
期刊介绍: Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信